Maternal Fc-mediated non-neutralizing antibody responses correlate with protection against congenital human cytomegalovirus infection.

TitleMaternal Fc-mediated non-neutralizing antibody responses correlate with protection against congenital human cytomegalovirus infection.
Publication TypeJournal Article
Year of Publication2022
AuthorsSemmes EC, Miller IG, Wimberly CE, Phan CT, Jenks JA, Harnois MJ, Berendam SJ, Webster H, Hurst JH, Kurtzberg J, Fouda GG, Walsh KM, Permar SR
JournalJ Clin Invest
Volume132
Issue16
Date Published2022 Aug 15
ISSN1558-8238
KeywordsAntibodies, Viral, Antibody Formation, Child, Cytomegalovirus, Cytomegalovirus Infections, Cytomegalovirus Vaccines, Herpesviridae Infections, Humans, Immunoglobulin G, Prospective Studies
Abstract

Human cytomegalovirus (HCMV) is the most common congenital infection and a leading cause of stillbirth, neurodevelopmental impairment, and pediatric hearing loss worldwide. Development of a maternal vaccine or therapeutic to prevent congenital HCMV has been hindered by limited knowledge of the immune responses that protect against HCMV transmission in utero. To identify protective antibody responses, we measured HCMV-specific IgG binding and antiviral functions in paired maternal and cord blood sera from HCMV-seropositive transmitting (n = 41) and non-transmitting (n = 40) mother-infant dyads identified via a large, US-based, public cord blood bank. We found that high-avidity IgG binding to HCMV and antibody-dependent cellular phagocytosis (ADCP) were associated with reduced risk of congenital HCMV infection. We also determined that HCMV-specific IgG activation of FcγRI and FcγRII was enhanced in non-transmitting dyads and that increased ADCP responses were mediated through both FcγRI and FcγRIIA expressed on human monocytes. These findings suggest that engagement of FcγRI/FcγRIIA and Fc effector functions including ADCP may protect against congenital HCMV infection. Taken together, these data can guide future prospective studies on immune correlates against congenital HCMV transmission and inform HCMV vaccine and immunotherapeutic development.

DOI10.1172/JCI156827
Alternate JournalJ Clin Invest
PubMed ID35763348
PubMed Central IDPMC9374380
Grant ListR21 CA242439 / CA / NCI NIH HHS / United States
T32 AI052077 / AI / NIAID NIH HHS / United States